{"transactions":[{"id":4639311,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Emplopyee Stock Option (Right to Buy)","published_at":"2026-10-13T20:10:08.000Z","date":"2026-10-09","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4th) of the shares subject to the option award shall vest on September 2, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":37.22,"expiration_date":"2036-10-08","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001746372-26-000007","document":"form4-10132026_041004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746372/000174637226000007/form4-10132026_041004.xml","form_type":"4"}},{"id":4639315,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":183958,"kind":"person","name":"Kozauer Susan Gani","position":1,"cik":"0002150267","reported_name":"Kozauer Susan Gani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Emplopyee Stock Option (Right to Buy)","published_at":"2026-10-13T20:10:05.000Z","date":"2026-10-09","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4th) of the shares subject to the option award shall vest on September 14, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":37.22,"expiration_date":"2036-10-08","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0002150267-26-000005","document":"form4-10132026_041001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2150267/000215026726000005/form4-10132026_041001.xml","form_type":"4"}},{"id":699056,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-08-03T23:28:30.000Z","date":"2026-07-30","kind":"purchase","planned":false,"acquired":true,"shares":286205,"price":34.9399,"value":9999974.0795,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":664649,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":286205},"source":{"system":"sec-edgar","filing":"0001193125-26-331058","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000119312526331058/ownership.xml","form_type":"4"}},{"id":747950,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T22:04:35.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":27.95,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001187308-26-000002","document":"form4-06052026_100631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000118730826000002/form4-06052026_100631.xml","form_type":"4"}},{"id":747949,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T21:35:07.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":27.95,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001609805-26-000003","document":"form4-06052026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000160980526000003/form4-06052026_090603.xml","form_type":"4"}},{"id":747948,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40938,"kind":"person","name":"Luse Rebecca","position":1,"cik":"0002031342","reported_name":"Luse Rebecca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T21:32:20.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":27.95,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0002031342-26-000002","document":"form4-06052026_090613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000203134226000002/form4-06052026_090613.xml","form_type":"4"}},{"id":748283,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T21:26:45.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes an option award for 2,500 shares pursuant to the Issuer's non-employee director compensation policy which represents a prorated annual grant for the previous year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":27.95,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001992908-26-000011","document":"form4-06052026_090641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000199290826000011/form4-06052026_090641.xml","form_type":"4"}},{"id":747947,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":36308,"kind":"person","name":"Hemrajani Rekha","position":1,"cik":"0001771213","reported_name":"Hemrajani Rekha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T21:25:17.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":27.95,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001771213-26-000002","document":"form4-06052026_090613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000177121326000002/form4-06052026_090613.xml","form_type":"4"}},{"id":748128,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40967,"kind":"person","name":"Kane William P Jr","position":1,"cik":"0001813937","reported_name":"Kane William P Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T21:23:51.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":27.95,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001813937-26-000003","document":"form4-06052026_090647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813937/000181393726000003/form4-06052026_090647.xml","form_type":"4"}},{"id":747946,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":35913,"kind":"person","name":"Garland J. Scott","position":1,"cik":"0001533228","reported_name":"Garland J. Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T21:22:34.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":27.95,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001533228-26-000006","document":"form4-06052026_090631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000153322826000006/form4-06052026_090631.xml","form_type":"4"}},{"id":851367,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":19968,"kind":"person","name":"Lenz Robert A.","position":1,"cik":"0001992908","reported_name":"Lenz Robert A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-10T20:19:34.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option award shall vest in three (3) equal annual installments on March 6, 2027, March 6, 2028 and March 6, 2029, subject to the Reporting Person's continuous service through each such date."}],"balance_after":20000,"derivative":{"exercise_price":23.78,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001992908-26-000007","document":"form4-03102026_080331.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992908/000199290826000007/form4-03102026_080331.xml","form_type":"4"}},{"id":912469,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67079,"kind":"organization","name":"Deep Track Special Opportunities Fund, LP","position":2,"cik":"0002077950","reported_name":"Deep Track Special Opportunities Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":3,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":4,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-02-10T16:30:04.000Z","date":"2026-02-06","kind":"purchase","planned":false,"acquired":true,"shares":93925,"price":21.1699,"value":1988382.8575,"ownership":{"direct":false,"nature":"By Deep Track Special Opportunities Fund, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":93925,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":93925},"source":{"system":"sec-edgar","filing":"0001193125-26-044776","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2077950/000119312526044776/ownership.xml","form_type":"4"}},{"id":912468,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67079,"kind":"organization","name":"Deep Track Special Opportunities Fund, LP","position":2,"cik":"0002077950","reported_name":"Deep Track Special Opportunities Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":3,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":4,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-02-10T16:30:04.000Z","date":"2026-02-06","kind":"purchase","planned":false,"acquired":true,"shares":378444,"price":21.1699,"value":8011621.6356,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":378444,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":378444},"source":{"system":"sec-edgar","filing":"0001193125-26-044776","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2077950/000119312526044776/ownership.xml","form_type":"4"}},{"id":972668,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":71801,"kind":"person","name":"Pai Panandiker Kaya Kamlesh","position":1,"cik":"0002095250","reported_name":"Pai Panandiker Kaya Kamlesh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-11T21:15:13.000Z","date":"2025-12-10","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on November 10, 2026 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments on the last calendar day of each month with the first monthly installment occurring on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":195000,"derivative":{"exercise_price":21.36,"expiration_date":"2035-12-09","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0002095250-25-000006","document":"form4-12112025_041206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000209525025000006/form4-12112025_041206.xml","form_type":"4"}},{"id":1031207,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":90525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":90525,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":90525},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1031206,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":7171,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":7171,"derivative":{"exercise_price":15,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":7171},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1031205,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7171,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":7171},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1031204,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":14343,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":14343,"derivative":{"exercise_price":15,"expiration_date":"2033-08-24","underlying":"Common Stock","underlying_shares":14343},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1031203,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14343,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2033-08-24","underlying":"Common Stock","underlying_shares":14343},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1031202,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":1255,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":1255,"derivative":{"exercise_price":15,"expiration_date":"2030-08-30","underlying":"Common Stock","underlying_shares":1255},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1031201,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1255,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":69.72,"expiration_date":"2030-08-30","underlying":"Common Stock","underlying_shares":1255},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1031200,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":896,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":896,"derivative":{"exercise_price":15,"expiration_date":"2029-12-22","underlying":"Common Stock","underlying_shares":896},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1031199,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":896,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":69.72,"expiration_date":"2029-12-22","underlying":"Common Stock","underlying_shares":896},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1031198,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":3944,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":3944,"derivative":{"exercise_price":15,"expiration_date":"2028-11-13","underlying":"Common Stock","underlying_shares":3944},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1031197,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74891,"kind":"person","name":"PANOFF MARC L","position":1,"cik":"0001304340","reported_name":"PANOFF MARC L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-30T00:16:33.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3944,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":64.15,"expiration_date":"2028-11-13","underlying":"Common Stock","underlying_shares":3944},"source":{"system":"sec-edgar","filing":"0001304340-25-000006","document":"form4-09302025_120930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000130434025000006/form4-09302025_120930.xml","form_type":"4"}},{"id":1039544,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-09-16T22:09:13.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":false,"shares":16666667,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":686138},"source":{"system":"sec-edgar","filing":"0002015536-25-000007","document":"form4-09162025_100907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000201553625000007/form4-09162025_100907.xml","form_type":"4"}},{"id":1039543,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T22:09:13.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":666666,"price":15,"value":9999990.0,"ownership":{"direct":false,"nature":"By Deep Track Special Opportunities Fund, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held by Deep Track Special Opportunities Fund, LP.   Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":666666,"source":{"system":"sec-edgar","filing":"0002015536-25-000007","document":"form4-09162025_100907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000201553625000007/form4-09162025_100907.xml","form_type":"4"}},{"id":1039542,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T22:09:13.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":2000000,"price":15,"value":30000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":2686138,"source":{"system":"sec-edgar","filing":"0002015536-25-000007","document":"form4-09162025_100907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000201553625000007/form4-09162025_100907.xml","form_type":"4"}},{"id":1039541,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T22:09:13.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":true,"shares":686138,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":686138,"source":{"system":"sec-edgar","filing":"0002015536-25-000007","document":"form4-09162025_100907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000201553625000007/form4-09162025_100907.xml","form_type":"4"}},{"id":1039382,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-09-16T20:15:07.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":false,"shares":10000000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"Consists of (i) 6,362,625 shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":411681},"source":{"system":"sec-edgar","filing":"0001726334-25-000003","document":"form4-09162025_040904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000172633425000003/form4-09162025_040904.xml","form_type":"4"}},{"id":1039381,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T20:15:07.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":15,"value":15000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of (i) 636,263 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 363,737 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":1411681,"source":{"system":"sec-edgar","filing":"0001726334-25-000003","document":"form4-09162025_040904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000172633425000003/form4-09162025_040904.xml","form_type":"4"}},{"id":1039380,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T20:15:07.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":true,"shares":411681,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":411681,"source":{"system":"sec-edgar","filing":"0001726334-25-000003","document":"form4-09162025_040904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000172633425000003/form4-09162025_040904.xml","form_type":"4"}},{"id":1039355,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-09-16T20:15:05.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":false,"shares":10000000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"Consists of (i) 6,362,625 shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":411681},"source":{"system":"sec-edgar","filing":"0001609805-25-000006","document":"form4-09162025_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000160980525000006/form4-09162025_040901.xml","form_type":"4"}},{"id":1039354,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T20:15:05.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":15,"value":15000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of (i) 636,263 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 363,737 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":1411681,"source":{"system":"sec-edgar","filing":"0001609805-25-000006","document":"form4-09162025_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000160980525000006/form4-09162025_040901.xml","form_type":"4"}},{"id":1039353,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T20:15:05.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":true,"shares":411681,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":411681,"source":{"system":"sec-edgar","filing":"0001609805-25-000006","document":"form4-09162025_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000160980525000006/form4-09162025_040901.xml","form_type":"4"}},{"id":1039877,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":false,"shares":30667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vida Ventures III-A, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Vida Ventures III-A, L.P. (\"Vida III-A\"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1262},"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1039876,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":false,"shares":13302666,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vida Ventures III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vida Ventures III, L.P. (\"Vida III\"). Vida Ventures GP III, L.L.C. (\"Vida III GP\") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an \"Investment Committee Member\" and such committee, the \"Investment Committee\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":547648},"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1039875,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":767,"price":15,"value":11505.0,"ownership":{"direct":false,"nature":"By Vida Ventures III-A, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Vida Ventures III-A, L.P. (\"Vida III-A\"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":2029,"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1039874,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":332566,"price":15,"value":4988490.0,"ownership":{"direct":false,"nature":"By Vida Ventures III, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vida Ventures III, L.P. (\"Vida III\"). Vida Ventures GP III, L.L.C. (\"Vida III GP\") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an \"Investment Committee Member\" and such committee, the \"Investment Committee\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":880214,"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1039873,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":true,"shares":1262,"ownership":{"direct":false,"nature":"By Vida Ventures III-A, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Vida Ventures III-A, L.P. (\"Vida III-A\"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":1262,"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1039872,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":true,"shares":547648,"ownership":{"direct":false,"nature":"By Vida Ventures III, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vida Ventures III, L.P. (\"Vida III\"). Vida Ventures GP III, L.L.C. (\"Vida III GP\") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an \"Investment Committee Member\" and such committee, the \"Investment Committee\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":547648,"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1041619,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":36308,"kind":"person","name":"Hemrajani Rekha","position":1,"cik":"0001771213","reported_name":"Hemrajani Rekha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:23.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":22449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":22449,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":22449},"source":{"system":"sec-edgar","filing":"0001415889-25-024452","document":"form4-09122025_060919.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024452/form4-09122025_060919.xml","form_type":"4"}},{"id":1041606,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40938,"kind":"person","name":"Luse Rebecca","position":1,"cik":"0002031342","reported_name":"Luse Rebecca","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:22.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":22449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":22449,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":22449},"source":{"system":"sec-edgar","filing":"0001415889-25-024451","document":"form4-09122025_060917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024451/form4-09122025_060917.xml","form_type":"4"}},{"id":1041660,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40967,"kind":"person","name":"Kane William P Jr","position":1,"cik":"0001813937","reported_name":"Kane William P Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:20.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":22449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":22449,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":22449},"source":{"system":"sec-edgar","filing":"0001415889-25-024450","document":"form4-09122025_060915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813937/000141588925024450/form4-09122025_060915.xml","form_type":"4"}},{"id":1041600,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":22449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":22449,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":22449},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041599,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":10757,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10757,"derivative":{"exercise_price":15,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":10757},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041598,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10757,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":10757},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041597,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":717,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":717,"derivative":{"exercise_price":15,"expiration_date":"2030-08-24","underlying":"Common Stock","underlying_shares":717},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041596,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":717,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":69.72,"expiration_date":"2030-08-24","underlying":"Common Stock","underlying_shares":717},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041595,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":1792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":1792,"derivative":{"exercise_price":15,"expiration_date":"2028-06-26","underlying":"Common Stock","underlying_shares":1792},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041594,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":69.72,"expiration_date":"2028-06-26","underlying":"Common Stock","underlying_shares":1792},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041841,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":22449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":22449,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":22449},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041840,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":53787,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":53787,"derivative":{"exercise_price":15,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":53787},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041839,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":53787,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":53787},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041838,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":17929,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":17929,"derivative":{"exercise_price":15,"expiration_date":"2033-08-24","underlying":"Common Stock","underlying_shares":17929},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041837,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17929,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2033-08-24","underlying":"Common Stock","underlying_shares":17929},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041836,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":1255,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":1255,"derivative":{"exercise_price":15,"expiration_date":"2030-08-30","underlying":"Common Stock","underlying_shares":1255},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041835,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1255,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":69.72,"expiration_date":"2030-08-30","underlying":"Common Stock","underlying_shares":1255},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041834,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":896,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":896,"derivative":{"exercise_price":15,"expiration_date":"2029-12-22","underlying":"Common Stock","underlying_shares":896},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041833,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":896,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":69.72,"expiration_date":"2029-12-22","underlying":"Common Stock","underlying_shares":896},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041832,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":3944,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":3944,"derivative":{"exercise_price":15,"expiration_date":"2028-11-13","underlying":"Common Stock","underlying_shares":3944},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041831,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75446,"kind":"person","name":"PRENSKY ZACHARY","position":1,"cik":"0001167585","reported_name":"PRENSKY ZACHARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:17.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3944,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":64.15,"expiration_date":"2028-11-13","underlying":"Common Stock","underlying_shares":3944},"source":{"system":"sec-edgar","filing":"0001415889-25-024448","document":"form4-09122025_060911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167585/000141588925024448/form4-09122025_060911.xml","form_type":"4"}},{"id":1041593,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:14.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":22449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":22449,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":22449},"source":{"system":"sec-edgar","filing":"0001415889-25-024447","document":"form4-09122025_100911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024447/form4-09122025_100911.xml","form_type":"4"}},{"id":1041605,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":35913,"kind":"person","name":"Garland J. Scott","position":1,"cik":"0001533228","reported_name":"Garland J. Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:13.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":22449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":22449,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":22449},"source":{"system":"sec-edgar","filing":"0001415889-25-024446","document":"form4-09122025_060909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024446/form4-09122025_060909.xml","form_type":"4"}},{"id":1041604,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":35913,"kind":"person","name":"Garland J. Scott","position":1,"cik":"0001533228","reported_name":"Garland J. Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:13.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":3585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on January 31, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":3585,"derivative":{"exercise_price":15,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":3585},"source":{"system":"sec-edgar","filing":"0001415889-25-024446","document":"form4-09122025_060909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024446/form4-09122025_060909.xml","form_type":"4"}},{"id":1041603,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":35913,"kind":"person","name":"Garland J. Scott","position":1,"cik":"0001533228","reported_name":"Garland J. Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:13.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on January 31, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":3585},"source":{"system":"sec-edgar","filing":"0001415889-25-024446","document":"form4-09122025_060909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024446/form4-09122025_060909.xml","form_type":"4"}},{"id":1041602,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":35913,"kind":"person","name":"Garland J. Scott","position":1,"cik":"0001533228","reported_name":"Garland J. Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:13.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":17929,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":17929,"derivative":{"exercise_price":15,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":17929},"source":{"system":"sec-edgar","filing":"0001415889-25-024446","document":"form4-09122025_060909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024446/form4-09122025_060909.xml","form_type":"4"}},{"id":1041601,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":35913,"kind":"person","name":"Garland J. Scott","position":1,"cik":"0001533228","reported_name":"Garland J. Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:13.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17929,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":17929},"source":{"system":"sec-edgar","filing":"0001415889-25-024446","document":"form4-09122025_060909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024446/form4-09122025_060909.xml","form_type":"4"}},{"id":1041592,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75432,"kind":"person","name":"Silva Richard Anthony","position":1,"cik":"0002085780","reported_name":"Silva Richard Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Technical Operations"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:11.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":80899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":80899,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":80899},"source":{"system":"sec-edgar","filing":"0001415889-25-024445","document":"form4-09122025_060907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024445/form4-09122025_060907.xml","form_type":"4"}},{"id":1041591,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75432,"kind":"person","name":"Silva Richard Anthony","position":1,"cik":"0002085780","reported_name":"Silva Richard Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Technical Operations"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:11.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":8964,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on February 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":8964,"derivative":{"exercise_price":15,"expiration_date":"2035-02-10","underlying":"Common Stock","underlying_shares":8964},"source":{"system":"sec-edgar","filing":"0001415889-25-024445","document":"form4-09122025_060907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024445/form4-09122025_060907.xml","form_type":"4"}},{"id":1041590,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75432,"kind":"person","name":"Silva Richard Anthony","position":1,"cik":"0002085780","reported_name":"Silva Richard Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Technical Operations"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:11.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8964,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on February 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2035-02-10","underlying":"Common Stock","underlying_shares":8964},"source":{"system":"sec-edgar","filing":"0001415889-25-024445","document":"form4-09122025_060907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024445/form4-09122025_060907.xml","form_type":"4"}},{"id":1041586,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75430,"kind":"person","name":"Eramo Anna","position":1,"cik":"0002030921","reported_name":"Eramo Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:09.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":155812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":155812,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":155812},"source":{"system":"sec-edgar","filing":"0001415889-25-024444","document":"form4-09122025_060905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024444/form4-09122025_060905.xml","form_type":"4"}},{"id":1041585,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75430,"kind":"person","name":"Eramo Anna","position":1,"cik":"0002030921","reported_name":"Eramo Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:09.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":6275,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":6275,"derivative":{"exercise_price":15,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":6275},"source":{"system":"sec-edgar","filing":"0001415889-25-024444","document":"form4-09122025_060905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024444/form4-09122025_060905.xml","form_type":"4"}},{"id":1041584,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75430,"kind":"person","name":"Eramo Anna","position":1,"cik":"0002030921","reported_name":"Eramo Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:09.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6275,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":6275},"source":{"system":"sec-edgar","filing":"0001415889-25-024444","document":"form4-09122025_060905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024444/form4-09122025_060905.xml","form_type":"4"}},{"id":1041583,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75430,"kind":"person","name":"Eramo Anna","position":1,"cik":"0002030921","reported_name":"Eramo Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:09.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":26893,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":26893,"derivative":{"exercise_price":15,"expiration_date":"2033-08-24","underlying":"Common Stock","underlying_shares":26893},"source":{"system":"sec-edgar","filing":"0001415889-25-024444","document":"form4-09122025_060905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024444/form4-09122025_060905.xml","form_type":"4"}},{"id":1041582,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75430,"kind":"person","name":"Eramo Anna","position":1,"cik":"0002030921","reported_name":"Eramo Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:09.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26893,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2033-08-24","underlying":"Common Stock","underlying_shares":26893},"source":{"system":"sec-edgar","filing":"0001415889-25-024444","document":"form4-09122025_060905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024444/form4-09122025_060905.xml","form_type":"4"}},{"id":1041589,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75431,"kind":"person","name":"Soffer Gad","position":1,"cik":"0001612090","reported_name":"Soffer Gad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:07.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":229860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":229860,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":229860},"source":{"system":"sec-edgar","filing":"0001415889-25-024443","document":"form4-09122025_060903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024443/form4-09122025_060903.xml","form_type":"4"}},{"id":1041588,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75431,"kind":"person","name":"Soffer Gad","position":1,"cik":"0001612090","reported_name":"Soffer Gad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:07.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":26893,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":26893,"derivative":{"exercise_price":15,"expiration_date":"2035-02-10","underlying":"Common Stock","underlying_shares":26893},"source":{"system":"sec-edgar","filing":"0001415889-25-024443","document":"form4-09122025_060903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024443/form4-09122025_060903.xml","form_type":"4"}},{"id":1041587,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":75431,"kind":"person","name":"Soffer Gad","position":1,"cik":"0001612090","reported_name":"Soffer Gad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:07.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26893,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2035-02-10","underlying":"Common Stock","underlying_shares":26893},"source":{"system":"sec-edgar","filing":"0001415889-25-024443","document":"form4-09122025_060903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024443/form4-09122025_060903.xml","form_type":"4"}},{"id":1041581,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":49640,"kind":"person","name":"Turner Heather D","position":1,"cik":"0001403571","reported_name":"Turner Heather D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:06.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":971828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such\nvesting date."}],"balance_after":971828,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":971828},"source":{"system":"sec-edgar","filing":"0001415889-25-024442","document":"form4-09122025_060901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024442/form4-09122025_060901.xml","form_type":"4"}},{"id":1041580,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":49640,"kind":"person","name":"Turner Heather D","position":1,"cik":"0001403571","reported_name":"Turner Heather D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:06.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":7857,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on November 18, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such\nvesting date."}],"balance_after":7857,"derivative":{"exercise_price":15,"expiration_date":"2035-01-13","underlying":"Common Stock","underlying_shares":7857},"source":{"system":"sec-edgar","filing":"0001415889-25-024442","document":"form4-09122025_060901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024442/form4-09122025_060901.xml","form_type":"4"}},{"id":1041579,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":49640,"kind":"person","name":"Turner Heather D","position":1,"cik":"0001403571","reported_name":"Turner Heather D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:06.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7857,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on November 18, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such\nvesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2035-01-13","underlying":"Common Stock","underlying_shares":7857},"source":{"system":"sec-edgar","filing":"0001415889-25-024442","document":"form4-09122025_060901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024442/form4-09122025_060901.xml","form_type":"4"}},{"id":1041578,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":49640,"kind":"person","name":"Turner Heather D","position":1,"cik":"0001403571","reported_name":"Turner Heather D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:06.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":175706,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on November 18, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such\nvesting date."}],"balance_after":175706,"derivative":{"exercise_price":15,"expiration_date":"2034-11-17","underlying":"Common Stock","underlying_shares":175706},"source":{"system":"sec-edgar","filing":"0001415889-25-024442","document":"form4-09122025_060901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024442/form4-09122025_060901.xml","form_type":"4"}},{"id":1041577,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":49640,"kind":"person","name":"Turner Heather D","position":1,"cik":"0001403571","reported_name":"Turner Heather D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:06.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":175706,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on November 18, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such\nvesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2034-11-17","underlying":"Common Stock","underlying_shares":175706},"source":{"system":"sec-edgar","filing":"0001415889-25-024442","document":"form4-09122025_060901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024442/form4-09122025_060901.xml","form_type":"4"}}]}